



<HTML>


<HEAD>








<TITLE> </TITLE>


<META NAME="subject" CONTENT=" ">


<META NAME="keywords" CONTENT=" ">


<META NAME="doccomm" CONTENT=" ">


</HEAD>


<BODY LINK="#0000ff" VLINK="#800080" BGCOLOR="#ffffff">





<FONT SIZE=2>


<B><P ALIGN="CENTER">&nbsp;</P>


<P ALIGN="CENTER">UNITED STATES </P>


<P ALIGN="CENTER">SECURITIES AND EXCHANGE COMMISSION </P>


</B><P ALIGN="CENTER">Washington, D.C. 20549 </P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="CENTER">________________________</P>


</FONT><B><FONT SIZE=4><P ALIGN="CENTER">FORM 8K </P>


</B></FONT><FONT SIZE=2><P ALIGN="CENTER">________________________</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="CENTER">CURRENT REPORT</P>


<P ALIGN="JUSTIFY"></P><DIR>





<P ALIGN="CENTER">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </P>


<P ALIGN="CENTER"></P>


<P ALIGN="CENTER">Date of report (date of earliest event reported):  December 29, 2004</P>


<P ALIGN="JUSTIFY"></P></DIR>





</FONT><B><FONT SIZE=5 COLOR="#808080"><P ALIGN="CENTER">CoTherix, Inc.</P>


</B></FONT><FONT SIZE=2><P ALIGN="CENTER">(Exact name of registrant as specified in its charter) </P>


<P ALIGN="JUSTIFY"></P></FONT>


<P ALIGN="CENTER"><CENTER><TABLE CELLSPACING=0 BORDER=0 WIDTH=716>


<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=14><DIR>





<B><FONT SIZE=2><P>&#9;&#9;Delaware</DIR>


</B></FONT></TD>


<TD WIDTH="22%" VALIGN="TOP" HEIGHT=14>


<B><FONT SIZE=2><P ALIGN="CENTER">000-50794</B></FONT></TD>


<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=14>


<B><FONT SIZE=2><P ALIGN="CENTER">04-3513144</B></FONT></TD>


</TR>


<TR><TD WIDTH="46%" VALIGN="TOP" HEIGHT=15><DIR>





<FONT SIZE=2><P ALIGN="CENTER">(State or other jurisdiction of incorporation or organization)</DIR>


</FONT></TD>


<TD WIDTH="22%" VALIGN="TOP" HEIGHT=15>


<FONT SIZE=2><P ALIGN="CENTER">(Commission File Number)</FONT></TD>


<TD WIDTH="32%" VALIGN="BOTTOM" HEIGHT=15>


<FONT SIZE=2><P ALIGN="CENTER">(I.R.S. employer identification number)</FONT></TD>


</TR>


</TABLE>


</CENTER></P>





<FONT SIZE=2><P ALIGN="JUSTIFY"></P>


<B><P ALIGN="CENTER">5000 Shoreline Court, Suite 101, South San Francisco, CA 94080</P>


</B><P ALIGN="CENTER">(Address of principal executive offices and zip code) </P>


<P ALIGN="JUSTIFY"></P>


<B><P ALIGN="CENTER">(650) 808-6500 </P>


</B><P ALIGN="CENTER">(Registrant's telephone number, including area code) </P>


<P ALIGN="JUSTIFY"></P>


<P>&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<B><P ALIGN="RIGHT"><A NAME="toc"></A></P>


<P ALIGN="RIGHT"></P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P>


<P>Item 8.01.&nbsp;  Other Events</P>


</B>


<P>On December 29, 2004, the U.S. Food and Drug Administration approved Ventavis<SUP>TM</SUP> (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms.  A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>


<P ALIGN="JUSTIFY"></P>


<B><P ALIGN="JUSTIFY">Item 9.01.  Financial Statements and Exhibits</P>


<P ALIGN="JUSTIFY"></P>


</B><P ALIGN="JUSTIFY">(c)  Exhibits</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&nbsp;</P><DIR>


<DIR>





<P ALIGN="JUSTIFY">99.1&#9;Press Release of CoTherix, Inc., dated December 29, 2004, regarding the U.S. Food and Drug Administration's approval of  Ventavis<SUP>TM</SUP> (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms, furnished in accordance with Item 8.01 of this Current Report on Form 8-K.</P>


<B><P ALIGN="JUSTIFY"></P>


</B><P ALIGN="JUSTIFY">&nbsp;</P></DIR>


</DIR>





<P ALIGN="JUSTIFY">The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed &quot;filed&quot; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<B><P ALIGN="CENTER">SIGNATURES </P>


</B><P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">Date:  December 29, 2004</P></FONT>


<P ALIGN="RIGHT"><TABLE CELLSPACING=0 BORDER=0 WIDTH=288>


<TR><TD VALIGN="BOTTOM" COLSPAN=2>


<B><FONT SIZE=2><P>CoTherix, Inc.</B></FONT></TD>


</TR>


<TR><TD WIDTH="9%" VALIGN="TOP">


<FONT SIZE=2><P>By: </FONT><FONT SIZE=1>&nbsp;</FONT></TD>


<TD WIDTH="91%" VALIGN="BOTTOM">


<FONT SIZE=2><P>/s/ Christine Gray-Smith</FONT></TD>


</TR>


<TR><TD VALIGN="TOP" COLSPAN=2 HEIGHT=55>


<FONT SIZE=2><P ALIGN="JUSTIFY">Christine Gray-Smith</P>


<P ALIGN="JUSTIFY">Executive Vice President and Chief Financial Officer</P>


</FONT></TD>


</TR>


</TABLE>


</P>





<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<P ALIGN="CENTER">&nbsp;</P>


<B><P ALIGN="CENTER">INDEX TO EHXIBITS FILED WITH</P>


<P ALIGN="CENTER">THE CURRENT REPORT ON FORM 8-K DATED DECEMBER 29, 2004</P>


<P ALIGN="CENTER"></P>


<U><P>Exhibit&#9;</U>&#9;&#9;<U>Description</P>


</U><DIR>


<DIR>


<DIR>


<DIR>


<DIR>


<DIR>





</B><P>99.1&#9;Press Release of CoTherix, Inc., dated December 29, 2004, regarding the U.S. Food and Drug Administration's approval of Ventavis<SUP>TM</SUP> (iloprost) Inhalation Solution for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms, furnished in accordance with Item 8.01 of this Current Report on Form 8-K.</P>


<B><P ALIGN="RIGHT"></P>


<P ALIGN="RIGHT">&nbsp;</P>


<P ALIGN="RIGHT">&nbsp;</P></DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</DIR>


</B></FONT></BODY>


</HTML>









